ALKS

Alkermes plc NASDAQ

Healthcare ·Biotechnology ·IE · alkermes.com

$34.17

After hrs $36.25 +0.00%

Mkt Cap $5.7B

52w Low $25.17 79.6% of range 52w High $36.48

50d MA $31.41 200d MA $30.18

P/E (TTM) 22.7x

EV/EBITDA 10.8x

P/B 3.0x

Debt/Equity 0.0x

ROE 13.3%

P/FCF 9.6x

RSI (14) —

ATR (14) —

Beta 0.39

50d MA $31.41

200d MA $30.18

Avg Volume 2.3M

About

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 25, 2026	BMO	0.43	0.34	-20.9%	33.39	-2.7%	-7.0%	-8.0%	-9.9%	-9.4%	-12.5%	—
Oct 28, 2025	BMO	0.42	0.49	+16.7%	29.72	+1.8%	+4.3%	+5.8%	+3.7%	+3.3%	+1.5%	—
Jul 29, 2025	BMO	0.41	0.52	+26.8%	26.15	+5.2%	+3.3%	+6.8%	+1.3%	+1.5%	+1.9%	—
May 1, 2025	BMO	0.25	0.13	-48.9%	28.77	-0.1%	+6.3%	+10.5%	+9.1%	+5.5%	+5.6%	—
Feb 12, 2025	BMO	0.81	1.04	+28.4%	31.96	+1.3%	+4.8%	+12.6%	+12.3%	+12.3%	+12.1%	—
Oct 24, 2024	BMO	0.74	0.72	-2.7%	27.85	-3.0%	-3.6%	-6.3%	-4.7%	-5.1%	-5.5%	—
Jul 24, 2024	BMO	0.70	0.70	+0.0%	25.00	+7.6%	+6.0%	+12.2%	+11.5%	+11.7%	+10.5%	—
May 1, 2024	BMO	0.59	0.44	-25.4%	24.54	-2.8%	-2.2%	-2.8%	-2.0%	-1.8%	+0.2%	—
Feb 15, 2024	BMO	0.46	0.48	+4.3%	27.99	+2.7%	+16.3%	+15.0%	+8.6%	+4.3%	+3.3%	—
Oct 25, 2023	BMO	0.44	0.64	+45.5%	25.32	-6.9%	-7.4%	-2.4%	-5.6%	-4.0%	-4.5%	—
Jul 26, 2023	BMO	0.48	0.55	+14.6%	30.84	-2.3%	-2.6%	-1.8%	-6.7%	-5.1%	-7.5%	—
Apr 26, 2023	BMO	0.00	0.01	+172.6%	30.51	-2.5%	-7.0%	-7.1%	-6.4%	-6.1%	-6.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 9	BofA Securities	Maintains	Neutral → Neutral	—	$34.77	$35.00	+0.7%	+0.4%	-4.1%	-2.9%	-2.6%	-4.5%
Mar 24	Piper Sandler	Maintains	Overweight → Overweight	—	$27.71	$27.39	-1.2%	+2.5%	+6.0%	+8.0%	+6.1%	+8.8%
Feb 26	Wells Fargo	Maintains	Overweight → Overweight	—	$31.04	$31.06	+0.1%	-1.0%	-3.0%	-2.5%	-5.9%	-5.7%
Feb 26	RBC Capital	Maintains	Outperform → Outperform	—	$31.04	$31.06	+0.1%	-1.0%	-3.0%	-2.5%	-5.9%	-5.7%
Feb 20	BofA Securities	Maintains	Neutral → Neutral	—	$32.00	$31.80	-0.6%	-0.3%	+0.6%	+4.3%	-3.0%	-4.0%
Nov 17	Truist	Maintains	Buy → Buy	—	$29.04	$29.36	+1.1%	+1.0%	+0.8%	-1.2%	-2.9%	-1.5%
Nov 13	Wells Fargo	Maintains	Overweight → Overweight	—	$31.41	$30.60	-2.6%	-1.3%	-7.5%	-6.6%	-6.8%	-8.7%
Nov 13	Deutsche Bank	Maintains	Buy → Buy	—	$31.41	$30.60	-2.6%	-1.3%	-7.5%	-6.6%	-6.8%	-8.7%
Nov 12	Truist	Maintains	Buy → Buy	—	$33.81	$27.97	-17.3%	-7.1%	-8.3%	-14.1%	-13.3%	-13.5%
Oct 29	Wells Fargo	Maintains	Overweight → Overweight	—	$31.00	$31.00	+0.0%	+1.5%	-0.6%	-1.0%	-2.7%	-2.0%
Oct 29	Needham	Maintains	Buy → Buy	—	$31.00	$31.00	+0.0%	+1.5%	-0.6%	-1.0%	-2.7%	-2.0%
Oct 27	Mizuho	Maintains	Outperform → Outperform	—	$29.80	$30.05	+0.8%	-0.3%	+4.0%	+5.5%	+3.4%	+3.0%
Oct 23	RBC Capital	Maintains	Outperform → Outperform	—	$31.09	$31.22	+0.4%	-3.4%	-4.1%	-4.4%	-0.3%	+1.2%
Oct 23	Piper Sandler	Maintains	Overweight → Overweight	—	$31.09	$31.22	+0.4%	-3.4%	-4.1%	-4.4%	-0.3%	+1.2%
Sep 26	RBC Capital	Upgrade	Sector Perform → Outperform	—	$27.13	$28.20	+3.9%	+2.8%	+7.0%	+10.6%	+13.0%	+15.2%
Sep 9	JP Morgan	Maintains	Neutral → Neutral	—	$28.45	$28.56	+0.4%	-2.1%	-5.3%	-2.6%	-5.2%	-6.8%
Sep 9	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$28.45	$28.56	+0.4%	-2.1%	-5.3%	-2.6%	-5.2%	-6.8%
Jul 30	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$27.00	$27.40	+1.5%	+3.4%	-1.9%	-1.7%	-1.3%	-1.5%
Jul 29	Needham	Maintains	Buy → Buy	—	$26.15	$27.50	+5.2%	+3.3%	+6.8%	+1.3%	+1.5%	+1.9%
Jul 21	Needham	Maintains	Buy → Buy	—	$29.22	$28.98	-0.8%	-8.8%	-7.5%	-6.9%	-9.2%	-10.6%
Jul 21	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$29.22	$28.98	-0.8%	-8.8%	-7.5%	-6.9%	-9.2%	-10.6%
Jun 17	UBS	Upgrade	Neutral → Buy	—	$29.42	$30.24	+2.8%	+1.2%	-0.3%	-1.1%	-0.5%	-0.2%
May 2	Baird	Maintains	Outperform → Outperform	—	$30.58	$31.02	+1.4%	+3.9%	+2.7%	-0.7%	-0.7%	-0.7%
May 2	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$30.58	$31.02	+1.4%	+3.9%	+2.7%	-0.7%	-0.7%	-0.7%
Apr 28	UBS	Maintains	Neutral → Neutral	—	$27.84	$27.93	+0.3%	+0.3%	+3.3%	+3.3%	+9.8%	+14.2%
Mar 27	Deutsche Bank	Maintains	Buy → Buy	—	$33.69	$34.41	+2.1%	-0.5%	-1.4%	-2.0%	-3.4%	-3.1%
Mar 4	UBS	Upgrade	Sell → Neutral	—	$34.11	$34.68	+1.7%	+3.8%	+3.4%	+1.6%	+0.7%	+3.3%
Feb 14	Goldman Sachs	Maintains	Buy → Buy	—	$36.00	$36.06	+0.2%	-0.3%	-0.3%	-0.4%	-1.4%	-1.9%
Feb 13	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$33.50	$33.62	+0.4%	+7.5%	+7.1%	+7.2%	+7.0%	+6.0%
Nov 13	Mizuho	Maintains	Outperform → Outperform	—	$29.23	$29.23	+0.0%	+0.0%	-3.0%	-3.6%	-5.7%	-6.0%
Nov 5	Stifel	Upgrade	Hold → Buy	—	$26.59	$27.87	+4.8%	+6.7%	+10.2%	+9.0%	+8.5%	+13.1%
Oct 25	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$26.85	$26.76	-0.3%	-2.8%	-1.2%	-1.5%	-2.0%	-4.3%
Oct 25	Piper Sandler	Maintains	Overweight → Overweight	—	$26.85	$26.76	-0.3%	-2.8%	-1.2%	-1.5%	-2.0%	-4.3%
Oct 25	JP Morgan	Maintains	Neutral → Neutral	—	$26.85	$26.76	-0.3%	-2.8%	-1.2%	-1.5%	-2.0%	-4.3%
Oct 25	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$26.85	$26.76	-0.3%	-2.8%	-1.2%	-1.5%	-2.0%	-4.3%
Oct 25	Goldman Sachs	Maintains	Buy → Buy	—	$26.85	$26.76	-0.3%	-2.8%	-1.2%	-1.5%	-2.0%	-4.3%
Oct 14	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$28.91	$28.63	-1.0%	+0.5%	-3.1%	-2.8%	-2.0%	-2.2%
Oct 10	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$26.59	$26.42	-0.6%	+2.9%	+8.7%	+9.3%	+5.3%	+5.6%
Sep 16	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$27.66	$27.78	+0.4%	+0.6%	+0.3%	+0.6%	+2.5%	+3.2%
Jul 25	Baird	Maintains	Outperform → Outperform	—	$26.51	$26.68	+0.6%	+5.8%	+5.2%	+5.3%	+4.2%	+3.1%
Jul 25	JP Morgan	Maintains	Neutral → Neutral	—	$26.51	$26.68	+0.6%	+5.8%	+5.2%	+5.3%	+4.2%	+3.1%
Jul 25	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$26.51	$26.68	+0.6%	+5.8%	+5.2%	+5.3%	+4.2%	+3.1%
Jul 25	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$26.51	$26.68	+0.6%	+5.8%	+5.2%	+5.3%	+4.2%	+3.1%
Jul 15	JP Morgan	Maintains	Neutral → Neutral	—	$23.57	$23.60	+0.1%	-0.8%	+4.4%	+4.4%	+4.6%	+5.3%
Jun 4	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$24.06	$24.14	+0.3%	-1.7%	+0.5%	+0.4%	-0.6%	+0.5%
May 23	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$24.21	$24.29	+0.3%	-0.9%	-0.8%	-1.9%	-3.8%	-4.1%
May 2	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$24.01	$23.87	-0.6%	-0.6%	+0.2%	+0.4%	+2.4%	+0.4%
Apr 19	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$23.76	$23.65	-0.5%	+0.4%	+1.3%	+2.1%	+3.7%	+2.9%
Apr 9	Jefferies	Maintains	Buy → Buy	—	$25.93	$27.29	+5.2%	+3.1%	+0.8%	-3.6%	-5.8%	-7.4%
Apr 1	Piper Sandler	Maintains	Overweight → Overweight	—	$27.07	$27.13	+0.2%	+0.6%	-1.1%	-2.7%	-4.7%	-3.5%

Recent Filings

8-K · 2.02 !! High

Alkermes plc -- 8-K 2.02: Earnings Results

Alkermes announced Q1 2026 results and revised full-year 2026 guidance, with updated financial expectations providing investors clarity on the company's performance trajectory and anticipated outcomes.

May 5

8-K

Alkermes Inc. plc -- 8-K Filing

Alkermes plc filed its Q4 2025 financial results, providing investors with year-end performance metrics and guidance for the biopharmaceutical company's future operations.

Feb 25

8-K · 5.02 !!! Very High

Alkermes Inc. plc -- 8-K 5.02: Executive Change

Alkermes appointed Blair C. Jackson as CEO effective July 31, 2026, signaling potential strategic leadership changes that investors should monitor for impact on company direction.

Feb 25

8-K · 2.01 !!! Very High

Alkermes Inc. plc -- 8-K 2.01: Acquisition Completed

Alkermes completed its acquisition of Avadel Pharmaceuticals, expanding its specialty pharma portfolio and potentially enhancing revenue streams through Avadel's existing product lineup and pipeline.

Feb 12

Data updated apr 24, 2026 5:19pm · Source: massive.com